Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,168 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting monocyte chemoattractant protein-1 signalling in disease.
Dawson J, Miltz W, Mir AK, Wiessner C. Dawson J, et al. Expert Opin Ther Targets. 2003 Feb;7(1):35-48. doi: 10.1517/14728222.7.1.35. Expert Opin Ther Targets. 2003. PMID: 12556201 Review.
Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment.
Dawson J, Engelhardt P, Kastelic T, Cheneval D, MacKenzie A, Ramage P. Dawson J, et al. Rheumatology (Oxford). 1999 May;38(5):401-6. doi: 10.1093/rheumatology/38.5.401. Rheumatology (Oxford). 1999. PMID: 10371276
Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases.
Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, Engelhardt P, Boes L, Schnyder J, Tschopp C, Urfer R, Baumann G. Vallon R, et al. J Immunol. 2001 Feb 15;166(4):2801-7. doi: 10.4049/jimmunol.166.4.2801. J Immunol. 2001. PMID: 11160347
Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Grosios K, et al. Inflamm Res. 2004 Apr;53(4):133-42. doi: 10.1007/s00011-003-1230-4. Epub 2004 Mar 18. Inflamm Res. 2004. PMID: 15060719
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ. Esser R, et al. Br J Pharmacol. 2005 Feb;144(4):538-50. doi: 10.1038/sj.bjp.0706078. Br J Pharmacol. 2005. PMID: 15655513 Free PMC article.
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O'Byrne L, Quadros E, Toutain PL, Lees P. King JN, et al. J Vet Pharmacol Ther. 2009 Feb;32(1):1-17. doi: 10.1111/j.1365-2885.2008.00962.x. J Vet Pharmacol Ther. 2009. PMID: 19161451
The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation.
Koziczak-Holbro M, Littlewood-Evans A, Pöllinger B, Kovarik J, Dawson J, Zenke G, Burkhart C, Müller M, Gram H. Koziczak-Holbro M, et al. Arthritis Rheum. 2009 Jun;60(6):1661-71. doi: 10.1002/art.24552. Arthritis Rheum. 2009. PMID: 19479877
Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, Burkhart C, Dawson J, Niwa S, Katopodis A, Nuesslein-Hildesheim B, Weckbecker G, Zenke G, Kinzel B, Traggiai E, Brenner D, Brüstle A, St Paul M, Zamurovic N, McCoy KD, Rolink A, Régnier CH, Mak TW, Ohashi PS, Patel DD, Calzascia T. Bornancin F, et al. J Immunol. 2015 Apr 15;194(8):3723-34. doi: 10.4049/jimmunol.1402254. Epub 2015 Mar 11. J Immunol. 2015. PMID: 25762782
2,168 results
Jump to page
Feedback